← All trials
NCT06646276
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2025
- Primary completion
- Apr 6, 2028
- Completion date
- Sep 5, 2031
- First posted
- Oct 17, 2024
- Last posted
- Nov 14, 2024
- Enrollment
- 530
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Bristol-Myers SquibbLead sponsor
- Bristol-Myers SquibbOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.